Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lot-to-lot consistency study of RSVPreF3 OA vaccine in adults ≥60 years
2021-002225-18Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoint: RSVPreF3-specific IgG GMC ratio at Day 30. Started Jun 2021; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-002225-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002225-18.